Table 1. Comparison of STL, pan-cancer MTL, and pan-disease MTL by ROC AUC and PR AUC for 17 cancer types with >0.5% prevalence.
| Diseases | Receiver operating characteristics (ROC) AUC# | Precision-recall (PR) AUC# | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| STL ROC AUC |
Pan-cancer MTL | Pan-disease MTL | STL PR AUC |
Pan-cancer MTL | Pan-disease MTL | Prevalence (Baseline) |
|||||
| ROC | Relative increase* | ROC | Relative increase* | PR | Relative increase* | PR | Relative increase* | ||||
| AUC | AUC | AUC | AUC | ||||||||
| Malignant melanoma | 52.80% | 59.20% | +234% | 58.10% | +194% | 1.33% | 1.70% | +790% | 1.61% | +593% | 1.28% |
| Non-melanoma skin cancer | 61.50% | 62.40% | +8% | 62.90% | +12% | 9.76% | 10.03% | +8% | 10.21% | +14% | 6.65% |
| Skin cancer | 61.00% | 61.80% | +7% | 61.90% | +8% | 10.40% | 10.73% | +11% | 10.86% | +15% | 7.32% |
| Lung cancer | 59.10% | 60.30% | +14% | 60.50% | +16% | 1.39% | 1.44% | +11% | 1.51% | +23% | 0.90% |
| Intrathoracic cancer | 59.10% | 60.70% | +18% | 61.00% | +21% | 1.54% | 1.58% | +7% | 1.65% | +20% | 1.01% |
| Colorectal cancer | 54.40% | 56.40% | +46% | 57.10% | +60% | 2.00% | 2.21% | +71% | 2.29% | +100% | 1.72% |
| Colon cancer | 53.90% | 55.70% | +47% | 56.10% | +59% | 1.38% | 1.49% | +51% | 1.49% | +53% | 1.17% |
| Rectal cancer | 54.70% | 57.90% | +69% | 59.30% | +100% | 0.77% | 0.88% | +98% | 0.89% | +116% | 0.67% |
| Bladder cancer | 64.50% | 67.90% | +24% | 68.40% | +27% | 0.80% | 0.87% | +24% | 0.92% | +42% | 0.51% |
| Uterine cancer | 51.20% | 53.20% | +177% | 51.80% | +50% | 1.08% | 1.18% | +224% | 1.10% | +49% | 1.04% |
| Cervical cancer | 55.20% | 55.40% | +4% | 56.50% | +24% | 1.80% | 1.88% | +35% | 1.97% | +76% | 1.58% |
| Prostate cancer | 60.00% | 59.70% | -3% | 59.60% | -4% | 8.33% | 8.53% | +9% | 8.37% | +2% | 6.06% |
| Breast cancer | 57.00% | 58.30% | +19% | 58.10% | +16% | 9.38% | 9.67% | +13% | 9.79% | +20% | 7.25% |
| Female genital tract cancer | 54.00% | 54.30% | +7% | 54.50% | +11% | 3.15% | 3.27% | +41% | 3.39% | +84% | 2.86% |
| Male genital tract cancer | 53.60% | 56.10% | +68% | 54.50% | +24% | 2.57% | 2.73% | +57% | 2.59% | +9% | 2.28% |
| Lymphoma | 50.40% | 56.80% | +1442% | 57.90% | +1704% | 0.73% | 0.82% | +102% | 0.82% | +98% | 0.64% |
| Non-hodgkins lymphoma | 52.10% | 56.60% | +220% | 57.80% | +278% | 0.61% | 0.68% | +81% | 0.69% | +95% | 0.53% |
#Best AUC highlighted in bold
*